Azar Shahraz

4PUBLICATIONS
5CO-AUTHORS
Molecular targetsClinical pharmacology and therapeutics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Aug 25, 2026
Population Pharmacokinetics and Exposure-Response Analyses of Savolitinib Alone or in Combination With Osimertinib in Patients With Locally Advanced or Metastatic Solid Tumors.

|Dec 26, 2025
Clinical Pharmacology Perspective on Direct-To-Subcutaneous Dosing of T Cell Engagers in Oncology First-In-Human Studies.

Wenlian Qiao, Azar Shahraz, Karthick Vishwanathan

|Sep 16, 2025
Reply to "High Pharmacokinetic Variability and Unrecognized Limitations in First-Line Osimertinib Plus Chemotherapy for EGFR-Mutated NSCLC".

Azar Shahraz, Jincheng Yang, Diansong Zhou

|Jul 10, 2025
Population Pharmacokinetics and Exposure-Response Analysis of First-Line Osimertinib Plus Chemotherapy in Patients with EGFR-Mutated Advanced NSCLC.

Jincheng Yang, Damilola Olabode, Aarti Sawant-Basak

Pageof 1

Frequent Collaborators

2 joint publications

Diansong Zhou

1 joint publications

Richard Baldry

1 joint publications

Wenlian Qiao

1 joint publications

Karthick Vishwanathan